Dr. Den Discusses Bone Metastases in Prostate Cancer | OncLive

Dr. Den Discusses Bone Metastases in Prostate Cancer

April 4, 2018

Robert B. Den, MD, associate professor of radiation oncology, Thomas Jefferson University Hospital, discusses bone metastases in prostate cancer.

Robert B. Den, MD, associate professor of radiation oncology, Thomas Jefferson University Hospital, discusses bone metastases in prostate cancer.

Prostate cancer is a unique malignancy, as it tends to have a preponderance of metastases to the bone. Bone metastases can impact a patient’s quality of life by causing severe bone pain, which is an area where investigators have been looking into targeting the bone microenvironment specifically.

Commonly used bone-targeted agents for the treatment of patients with metastatic castration-resistant prostate cancer include zoledronic acid (Zometa), denosumab (Xgeva), and radium-223 dichloride (Xofigo). These agents are designed to target the makeup of the bone, Den explains.


x